Clinical trials: Dementia Severe
Alzheimer Disease
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
- Trial name
- NCT04538066
- Testing
- Bryostatin 1
- Where
- 19 sites in United States
- Volunteers
- 122 people
- Sponsor
- Neurotrope Bioscience, Inc.
Sepsis, Respiratory Failure
Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure
Patients with infections in their blood often become very sick. These patients are usually put in an intensive care unit for careful observation and treatment.
- Conditions
- Sepsis, Respiratory Failure, Agitation
- Trial name
- PRO-DEFENSE (NCT02203019)
- Testing
- Propofol, Dexmedetomidine, Fentanyl
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Texas Tech University Health Sciences Center
Dementia, Dementia, Vascular
Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Millions of Americans have late-stage Alzheimer's and related dementias (ADRD), causing suffering due to loss of awareness of self and family, progressive dependency, physical and neuropsychiatric symptoms, and physical…
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal
- Trial name
- ADRD-PC (NCT04948866)
- Testing
- ADRD-PC Program
- Where
- 5 sites in United States
- Volunteers
- 884 people
- Sponsor
- University of North Carolina, Chapel Hill
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Autism Spectrum Disorder, Developmental Disability
Propranolol for Challenging Behaviors in Autism
Severe challenging behaviors such as aggression and self-injury can cause significant morbidity and decrease the quality of life for individuals with Autism Spectrum Disorders (ASD).
- Conditions
- Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior
- Trial name
- NCT04047355
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rutgers, The State University of New Jersey
Alzheimer Disease, Dementia
Faith-Based Toolbox for African Americans With Dementia
The purpose of this study is to create and test faith-based activities that might be useful for African American adults with moderate and severe dementia and their caregivers.
- Trial name
- NCT04325204
- Testing
- Faith-based Home Activity Toolbox (Faith-HAT)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Emory University
Aggression, Self-Injurious Behavior
Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control
Children with an intellectual disability often display severe destructive behavior (e.g., aggression, self-injury) that pose risks to themselves or others and represent barriers to community integration.
- Trial name
- NCT02483572
- Testing
- Functional Communication Training
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Nebraska
Parkinson's Disease Dementia
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's…
- Trial name
- NCT00623103
- Testing
- Rivastigmine capsule, Rivastigmine transdermal patch
- Where
- 127 sites in United States, Argentina and 11 more
- Volunteers
- 583 people
- Sponsor
- Novartis
Severe Alzheimer Disease
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
- Trial name
- NCT03765762
- Testing
- GRF6019
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alkahest, Inc.
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Memantine and Antipsychotics Use
To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.
- Trial name
- MemAP (NCT00649220)
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Merz Pharmaceuticals GmbH
Alzheimer's Disease
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.
- Trial name
- NCT02431468
- Testing
- Bryostatin 1
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Neurotrope Bioscience, Inc.
Alzheimer's Disease
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease.
- Trial name
- NCT00566501
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 915 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
- Trial name
- NCT01766336
- Testing
- Group 1 ELND005, Group 2 ELND005
- Where
- 46 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- OPKO Health, Inc.
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Alzheimer's Disease
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.
- Trial name
- NCT00478205
- Testing
- Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
- Where
- United States
- Volunteers
- 1,467 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are…
- Trial name
- NCT00912288
- Testing
- Dimebon 20 mg po TID
- Where
- 47 sites in United States, Canada and 6 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Brain Injuries, Craniocerebral Trauma
DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury
The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traumatic Brain Injury (TBI).
- Conditions
- Brain Injuries, Craniocerebral Trauma, Trauma, Nervous System, Traumatic Brain Injury
- Trial name
- NCT01322048
- Testing
- IV Propranolol and Per Tube Clonidine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt University
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute